Autoantibodies are infrequently detected in the sera of patients with the demyelinating form of Guillain-Barré syndrome most commonly encountered in the Western world, despite abundant circumstantial evidence suggesting their existence. We hypothesised that antibody specificities reliant on the cis interactions of neighbouring membrane glycolipids could explain this discrepancy, and would not have been detected by traditional serological assays using highly purified preparations of single gangliosides. To assess the frequency of glycolipid complex antibodies in a Western European cohort of patients GBS we used a newly developed combinatorial glycoarray methodology to screen against large range of antigens (11 gangliosides, 8 other single glycolipids and 162 heterodimeric glycolipid complexes). Serum samples of 181 patients from a geographically defined, Western European cohort of GBS cases were analysed, along with 161 control sera. Serum IgG binding to single gangliosides was observed in 80.0% of axonal GBS cases, but in only 11.8% of cases with demyelinating electrophysiology. The inclusion of glycolipid complexes increased the positivity rate in demyelinating disease to 62.4%. There were 40 antigens with statistically significantly increased binding intensities in GBS as compared to healthy control sera. Of these, 7 complex antigens and 1 single ganglioside also produced statistically significantly increased binding intensities in GBS versus neurological disease controls. The detection of antibodies against specific complexes was associated with particular clinical features including disease severity, requirement for mechanical ventilation, and axonal electrophysiology. This study demonstrates that while antibodies against single gangliosides are often found in cases with axonal-type electrophysiology, antibodies against glycolipid complexes predominate in cases with demyelinating electrophysiology, providing a more robust serum biomarker than has ever been previously available for such cases. This work confirms the activation of the humoral immune system in the dysimmune disease process in GBS, and correlates patterns of antigen recognition with different clinical features.
References
[1]
Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S et al. (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci27(15): 3956-3967. doi:10.1523/JNEUROSCI.4401-06.2007. PubMed: 17428969.
[2]
Yuki N (2007) Ganglioside mimicry and peripheral nerve disease. Muscle and Nerve35(6): 691-711. doi:10.1002/mus.20762.
[3]
Goodyear CS, O’Hanlon GM, Plomp JJ, Wagner ER, Morrison I et al. (1999) Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J_Clin_Invest 104: 697–708.
[4]
Halstead SK, O’Hanlon GM, Humphreys PD, Morrison DB, Morgan BP et al. (2004) Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127: 2109–2123. doi:10.1093/brain/awh231. PubMed: 15289269.
Willison HJ (2007) Gangliosides as targets for autoimmune injury to the nervous system. J Neurochem103 Suppl 1: 143-149. doi:10.1111/j.1471-4159.2007.04718.x. PubMed: 17986149.
[7]
Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 Suppl: S21–S24. doi:10.1002/ana.410270707. PubMed: 2194422.
[8]
Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG (2001) Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur_Neurol 45: 133–139.
[9]
Svennerholm L, Bostr？m K, Fredman P, Jungbjer B, Lekman A et al. (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214: 115–123. PubMed: 7918590.
[10]
Nores GA, Lardone RD, Comín R, Alaniz ME, Moyano AL et al. (2008) Anti-GM1 antibodies as a model of the immune response to self-glycans. Biochim Biophys Acta 1780: 538–545. PubMed: 18029096.
[11]
Buchwald B, Zhang G, Vogt-Eisele AK, Zhang W, Ahangari R et al. (2007) Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis28(1): 113-121. doi:10.1016/j.nbd.2007.07.008. PubMed: 17720506.
[12]
Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K et al. (2004) Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann_Neurol 56: 567–571.
[13]
Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al. (2007) Anti-ganglioside complex antibodies associated with severe disability in GBS. JNeuroimmunol 182: 212–218.
[14]
Varki A (1994) Selectin ligands. Proc_Natl_Acad_Sci_U_S_A 91: 7390–7397. doi:10.1073/pnas.91.16.7390.
[15]
Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM et al. (2009) The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 119: 595–610. PubMed: 19221437.
[16]
Zitman FMP, Greenshields KN, Kuijf ML, Ueda M, Kaida K et al. (2011) Neuropathophysiological potential of Guillain–Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. Clinical and Experimental. Journal of Neuroimmunology 2: 59–67. doi:10.1111/j.1759-1961.2011.00022.x.
[17]
Rinaldi S, Brennan KM, Goodyear CS, O’Leary C, Schiavo G et al. (2009) Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology 19: 789–796. doi:10.1093/glycob/cwp049. PubMed: 19349623.
[18]
Rinaldi S, Brennan KM, Willison HJ (2010) Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding. Prog Lipid Res 49: 87–95. doi:10.1016/j.plipres.2009.09.001. PubMed: 19735674.
[19]
Mori K, Mahmood MI, Neya S, Matsuzaki K, Hoshino T (2012) Formation of GM1 ganglioside clusters on the lipid membrane containing sphingomyeline and cholesterol. J Phys Chem B 116: 5111–5121. doi:10.1021/jp207881k. PubMed: 22494278.
[20]
DeMarco ML (2012) Three-dimensional structure of glycolipids in biological membranes. Biochemistry 51: 5725–5732. doi:10.1021/bi3003633. PubMed: 22794115.
[21]
Van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363: 192–196. doi:10.1016/S0140-6736(03)15324-X. PubMed: 14738791.
[22]
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2: 750–753. PubMed: 80682.
[23]
Brennan KM, Galban-Horcajo F, Rinaldi S, O’Leary CP, Goodyear CS et al. (2011) Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol 238: 87–95. doi:10.1016/j.jneuroim.2011.08.002. PubMed: 21872346.
[24]
Hadden RDM, Cornblath DR, Hughes RaC, Zielasek J, Hartung H-P et al. (1998) Electrophysiological classification of guillain-barré syndrome: Clinical associations and outcome. Ann Neurol 44: 780–788. doi:10.1002/ana.410440512. PubMed: 9818934.
[25]
Kuijf ML, Van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW et al. (2005) Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 239: 37–44. doi:10.1016/j.jns.2005.07.009. PubMed: 16154154.
Yu RK, Yoshino H, Yamawaki M, Yoshino JE, Ariga T (1994) Subcellular Distribution of Sulfated Glucuronyl Glycolipids in Human Peripheral Motor and Sensory Nerves. J Biomed Sci 1: 167–171. PubMed: 11725022.
[28]
Li YT, M？nsson JE, Vanier MT, Svennerholm L (1973) Structure of the major glucosamine-containing ganglioside of human tissues. J Biol Chem 248: 2634–2636. PubMed: 4698234.
[29]
Jones CM, Athanasiou T (2005) Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 79: 16–20. doi:10.1016/j.athoracsur.2004.09.040. PubMed: 15620907.
[30]
Uncini A, Manzoli C, Notturno F, Capasso M (2010) Pitfalls in electrodiagnosis of Guillain–Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 81: 1157–1163. doi:10.1136/jnnp.2010.208538. PubMed: 20870864.
[31]
Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M et al. (2000) Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann_Neurol 48: 624–631.
[32]
McGonigal R, Rowan EG, Greenshields KN, Halstead SK, Humphreys PD et al. (2010) Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133: 1944–1960. doi:10.1093/brain/awq119. PubMed: 20513658.
[33]
Jacobs BC (2012) IGOS - International GSB Outcome Study | About IGOS. IGOS. Available: . https://www.gbsstudies.org/about-igos. Accessed 24 September 2012.
